NSE filing, NSE: SANDUMA. Summary written from the filing by ALFA Finder's alert engine.
Sandur Manganese & Iron Ores Ltd: key numbers
- Share price
- ₹169.83
- Market cap
- ₹8,256 Cr
- Revenue (annual)
- ₹5,088 Cr
- Net profit (annual)
- ₹656.6 Cr
- P/E (TTM)
- 11.5×Sector 16.7×
- Promoter holding
- 74.22%+0.00% QoQ
- FII holding
- 1.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandur Manganese & Iron Ores Ltd
All →Sandur Manganese & Iron Ores Board Meeting Date
Sandur Manganese & Iron Ores will hold a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window is closed from 1 October 2026 until 48 hours after the meeting.
Sandur Manganese & Iron Ores Capacity Expansion
SMIORE's subsidiary Royal Sandur MedTech leased 6.2 acres at AP MedTech Zone, Visakhapatnam for a medical devices manufacturing unit. This marks the company's entry into the medical devices segment.
- Execution
- 33-year lease tenure
- land for medical devices manufacturing unit
- 6.2 acres
Sandur Manganese & Iron Ores Other Announcement
Sandur Manganese & Iron Ores Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as required by SEBI regulations.
Sandur Manganese & Iron Ores Merger & Restructuring Worth ₹1 Cr
The Sandur Manganese & Iron Ores Ltd incorporated a new wholly owned subsidiary, Royal Sandur MedTech Private Limited, for medical devices and consumables manufacturing.
- Value
- ₹1.00 Cr
Sandur Manganese & Iron Ores Merger & Restructuring Worth ₹1 Cr
Sandur Manganese & Iron Ores approved the incorporation of a wholly-owned subsidiary, 'Royal Sandur MedTech Private Limited', with a capital investment of ₹1 Crore.
- Value
- ₹1.00 Cr
Sandur Manganese & Iron Ores Legal & Regulatory
Sandur Manganese & Iron Ores Ltd's subsidiary, Royal Sandur Metals Private Limited, received a customs penalty order of ₹0.12 Crore.
- Value
- ₹0.12 Cr
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.